Skip to main content
SpringerLink
Log in

Tamiflu labelling updated to warn of self-injury and delirium

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Roche Laboratories Inc.Important prescribing information: Roche Laboratories Inc. would like to advise you of a recent update to the TAMIFLU (Rm) (oseltamivir phosphate) package insert. Company Communication: [2 pages], 13 Nov 2006. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tamiflu labelling updated to warn of self-injury and delirium. React. Wkly. 1128, 3 (2006). https://doi.org/10.2165/00128415-200611280-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200611280-00007

Keywords

Search

Navigation